IMRN Immuron Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1660046 · Reporting currency AUD · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: AUD | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 | FY20212021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 7.29M | 4.90M | 1.80M | 765,193 | 145,776 |
| Cost of revenue | 2.52M | 1.57M | 495,558 | 241,691 | 51,071 |
| Gross profit | 4.77M | 3.34M | 1.31M | 523,502 | 94,705 |
| R&D expense | 3.60M | 5.38M | 2.59M | 657,715 | 1.37M |
| SG&A expense | 4.48M | 4.56M | 4.22M | 3.52M | 6.09M |
| Operating income | -5.34M | -5.80M | -3.57M | -2.87M | -8.38M |
| Interest expense | 7,305 | 7,576 | 9,652 | 6,184 | 13,761 |
| Pretax income | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M |
| Net income | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M |
| EBITDA | -5.29M | -5.76M | -3.52M | -2.84M | -8.34M |
| EPS (basic) | -2.26 | -3.04 | -1.66 | -1.25 | -3.79 |
| EPS (diluted) | -2.26 | -3.04 | -1.66 | -1.25 | -3.79 |
| Weighted avg. shares (diluted) | 230.94M | 227.86M | 227.80M | 227.58M | — |
| Balance sheet | |||||
| Cash & equivalents | 2.83M | 11.66M | 17.16M | 22.11M | 25.05M |
| Short-term investments | — | — | 404,117 | — | — |
| Receivables | 1.93M | 1.39M | 417,420 | 662,896 | 334,707 |
| Inventory | 1.77M | 1.58M | 839,968 | 326,578 | 292,532 |
| Current assets | 10.02M | 14.73M | 20.41M | 23.67M | 25.75M |
| PP&E, netmay include right-of-use assets (IFRS) | 113,950 | 154,347 | 200,133 | 226,736 | 33,741 |
| Total assets | 10.13M | 15.55M | 21.99M | 24.86M | 27.05M |
| Current liabilities | 1.97M | 2.70M | 2.22M | 1.50M | 1.12M |
| Total liabilities | 2.06M | 2.84M | 2.37M | 1.68M | 1.16M |
| Shareholders' equity | 8.07M | 12.71M | 19.62M | 23.18M | 25.90M |
| Shares outstanding | — | — | 18 | — | — |
| Cash flow statement | |||||
| Operating cash flow | -6.14M | -5.88M | -2.60M | -3.15M | -4.08M |
| Capital expenditure | — | 195 | 7,739 | 10,048 | 6,630 |
| Free cash flow | — | -5.88M | -2.60M | -3.16M | -4.09M |
| Investing cash flow | -2.90M | 327,561 | -2.62M | 11,737 | 2,574 |
| Financing cash flow | 199,747 | 829 | -44,667 | -42,448 | 26.48M |
| Depreciation & amortization | 49,688 | 45,981 | 48,662 | 26,613 | 43,662 |
| Stock-based compensation | 304,243 | 3,299 | 226,954 | 94,890 | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.